The use of the glutaminase inhibitor, CB-839, in combination with the CDK4/6 inhibitor, palbociclib, resulted in blocking cell cycle progression and improved anti-tumor activity in ER+ breast cancer [225]. Here, GLS is linked to breast cancer.